Walden Group Healthcare M&A Blog

  • Tecan Group Acquires Paramit for $1b

    6/29/2021
    Tecan Group Ltd, a $795m Switzerland-based global provider of laboratory instruments and solutions in life science research and clinical diagnostics, has acquired Paramit Corporation, a maker of electronics based medical devices and life science instruments. The deal accelerates Tecan's entry into medical devices and enhances Paramit's...
    Read More
  • DENTSPLY SIRONA Inc. Acquires Propel Orthodontics for $131M

    6/14/2021
    DENTSPLY SIRONA (Nasdaq: XRAY), a $3.3b provider of dental technologies, equipment and consumables has acquired Propel Orthodontics, developer of the VPro, a vibratory orthodontic device that seats aligners in 5 minutes a day for at-home use.  The VPro device is used with Propel’s Fastrack Mobile App that patients can use to track usage and...
    Read More
  • Japan-based Olympus Corporation Acquires Israel-based Medi-Tate

    6/2/2021
    Adds an in-office treatment for benign prostatic hyperplasia (BPH) treatment to Olympus’ leading urological devices portfolio.  Medi-Tate's “iTind” has received FDA de Novo authorization and a European CE mark.  Since November 2018, Olympus secured distribution rights to iTind via an initial investment.  The incidence of BPH is one of...
    Read More
  • GE Healthcare Buys Molecular Imaging Agent Producer Zionexa

    5/17/2021
    General Electric (NYSE: GE), through its $18b healthcare business GE Healthcare, has acquired France-based Zionexa, the developer of a positron emission tomography (PET) imaging agent, Cerianna, used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions in recurrent or metastatic breast cancer care.  Cerianna was...
    Read More
  • The Walden Group Advises ASICO, LLC in its Sale to Katena Products, Inc.

    4/28/2021
    The Walden Group is pleased to announce that it represented ASICO, LLC in its sale to Katena Products, Inc. The principals of ASICO engaged Walden, in large part, due to its substantial track record and experience in regard to ophthalmic industry transactions. Walden had represented: Katena in its 2009 sale to Cortec Group and its subsequent...
    Read More